You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雙鷺藥業(002038.SZ):獲得富馬酸替諾福韋二吡呋酯片藥品註冊證書
格隆匯 08-20 19:17

格隆匯 8 月 20日丨雙鷺藥業(002038.SZ)公佈,公司於近日收到國家藥品監督管理局(國家藥監局)核准簽發的富馬酸替諾福韋二吡呋酯片(0.3g)藥品註冊證書”。

富馬酸替諾福韋二吡呋酯片於2019117日獲國家藥品審評中心受理。產品系醫保乙類產品,具有抗病毒療效更強大、零耐藥和妊娠B級等優勢被各國慢性乙型肝炎防治指南一致推薦為治療慢性乙型肝炎的一線藥物,適用於治療成人12歲及以上兒童慢性乙型肝炎感染以及人類免疫缺陷病毒1型(HIV-1)感染富馬酸替諾福韋二吡呋酯片最初由美國吉利德研發。國內生產企業有正大天晴、廣生堂、成都倍特、齊魯製藥和安徽貝克等廠家。20191公司同時申報的規格0.15g0.20g,目前在審評審批

富馬酸替諾福韋二吡呋酯片的獲批上市,豐富公司在肝病領域的產品儲備該產品目前已列入第一批集採目錄,預計未來有價格降低的風險。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account